Notice2025-23691
Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 23, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 244 (Tuesday, December 23, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 244 (Tuesday, December 23, 2025)]
[Notices]
[Pages 60111-60112]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-23691]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Enhanced Tumor
Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Eunice Kennedy Shriver National Institute of Child Health
and Human Development, an institute of the National Institutes of
Health, United States Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the patent applications listed in the
Supplementary Information section of this notice to EnZeta
Immunotherapies, Inc., a company located in Coral Gables, FL.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center, representing the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, on or before January 7, 2026 will
be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Geoffrey E. Ravilious, Ph.D., NCI Technology
Transfer Center, Telephone: 240-276-6391; Email:
<a href="/cdn-cgi/l/email-protection#f196949e9797839488df839087989d989e8482b19f9899df969e87"><span class="__cf_email__" data-cfemail="5a3d3f353c3c283f2374283b2c333633352f291a343332743d352c">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. United States Provisional Patent Application No. 63/625,354
filed January 26, 2024, and entitled ``ENHANCED TUMOR REACTIVITY OF T
CELLS LACKING SIT1, LAX1, OR TRAT1'' [HHS Reference No. E-004-2024-0-
US-01];
2. International Patent Application No. PCT/US2025/013054 filed
January 24, 2025, and entitled ``ENHANCED TUMOR REACTIVITY OF T CELLS
LACKING SIT1, LAX1, OR TRAT1'' [HHS Reference No. E-004-2024-0-PC-01];
and
3. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or in
the future.
The patent rights in these inventions have been assigned to the
Government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the following:
``The use of the Licensed Patent Rights to develop, manufacture,
distribute, sell and use T-cell-based therapeutics for the treatment of
solid tumors, high-grade dysplasia and pre-neoplastic conditions.''
[[Page 60112]]
This technology describes modified T cell therapeutics that have
reduced expression of one or a combination of transmembrane adaptor
proteins SIT1, LAX1 and TRAT1. T cell-based therapeutics such as ex
vivo expanded tumor infiltrating lymphocytes (TIL) and chimeric antigen
receptor T-cells (CAR-T) have clinical utility against a limited number
of solid tumor types, most notably, melanoma. However, to date,
efficacy in patients has been limited due to several factors. The
subject invention potentially addresses the limited efficacy of T cell
therapeutics by reducing expression of SIT1, LAX1 and/or TRAT1 which
leads to enhanced T cell cytotoxic activity against tumor cells.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute, representing the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: December 18, 2025.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2025-23691 Filed 12-22-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 23, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.